Category Specific RSS

myelofibrosis

International expansion as more hospitals register for Pharmaxis’ cancer treatment trials

Clinical stage pharmaceutical company Pharmaxis (PXS: ASX) is full steam ahead with their Phase 2 clinical trial for flagship drug,…

4 years ago

Out-the-box thinkers are just what the myelofibrosis treatment market needs

The pharmaceutical industry is an incredibly competitive space with new drug discoveries cropping up all the time, giving hope that…

4 years ago

Making their mark: Pharmaxis to continue clinical trials in revolutionary anti-skin scarring drug

In the wake of their oversubscribed capital raising effort, clinical stage pharmaceutical company Pharmaxis (ASX: PXS) is forging ahead with…

4 years ago

Shareholders back Pharmaxis liver cancer treatment trials via oversubscribed capital raise

When the University of Rochester came knocking on the door of biopharmaceutical company Pharmaxis (ASX: PXS), it was a boost…

4 years ago

Global biotech funds commit $7.2m to breakthrough liver and bone cancer trials

Breakthrough clinical trials into new treatments for bone marrow and liver cancer will soon commence after experienced institutional biotech investors…

4 years ago